Bristol-myers Squibb Compnay

University of Washington

Emergent Product Development Seattle,llc

Trubion Pharmaceuticals, Inc.

Theripion, Inc.

Xoma Corporation

Other

Dartmouth College

Oncogen

Aptevo Research and Development LLC

Pacific Northwest Research Institute

Emory University

Bristol Meyers Squibb Company

Bristol-myers Squibb

Genetic Systems Corporation

Jeffrey A Ledbetter

Peter S Linsley

Martha Susan Hayden-Ledbetter

William Brady

Nitin Krishnaji Damle

Alejandro A Aruffo

Xizhang Sun

Lisa K Gilliland

Keith B Elkon

Jurgen Bajorath

Randy R Robinson

Alvin Y Liu

Randolph J Noelle

Edward A Clark

H Perry Fell

Martha S Hayden

Peter Armstrong Thompson

Peter A Kiener

Robert Peach

Teresa M Foy

Joyce M Zarling

Philip M Wallace

Sandy Alexander Simon

Michael L Diegel

Laura Sue Grosmaire

Patricia A Moran

Ingegerd E Hellstrom

Diane Hollenbaugh

Diane L Hollenbaugh

Keith Elkon

Ivan Stamenkovic

Mark A Kay

Lieping Chen

Lioudmila Tchistiakova

Philip Tan

Lynn Massman Rose

Charles G Cerveny

Jay Wesley Chaplin

Christian P Larsen

Robert S Mittler

Thomas C Pearson

Cecile Morales

Christy Anne Nilsson

Karl Erik Hellstr&ouml;m

Ingegerd Hellstr&ouml;m

Robert Bader

Christopher B Wilson

Perry Fell

Gosta Winberg

Karl Erik Hellstrom

Valerie Calabro

Maximillian T Follettie

Alwin Schuler

Vince Montes

Robert J Peach

Michel Schummer

Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.

Therapeutic nuclease compositions and methods

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

APOA-1 fusion polypeptides and related compositions

Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

Polynucleotides encoding paraoxonase fusion polypeptides

Paraoxonase fusion polypeptides and related compositions and methods

Polynucleotides encoding APOA1-PON1 fusion polypeptides

The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

CD37 immunotherapeutics and uses thereof

B-cell reduction using CD37-specific and CD20-specific binding molecules

Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.

Molecules that bind CD180, compositions and methods of use

The present invention provides novel CD180 binding molecules, methods for their identification, and methods for their use.

Growing community of inventors

Shoreline, WA, United States of America

Jeffrey A Ledbetter